138907-70-7

Basic information

• Product Name: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate
• Synonyms: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate;5-Amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester
• CAS NO: 138907-70-7
• Molecular Formula: C₁₂H₁₂FN₃O₂
• Molecular Weight: 249.2409832
• Mol File: 138907-70-7.mol

Chemical Properties

• Boiling Point: 388.74 °C at 760 mmHg
• Flash Point: 188.904 °C
• Appearance: /
• Density: 1.33
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(138907-70-7)
• EPA Substance Registry System: ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate(138907-70-7)

Safety Data

• Hazardous Substances Data: 138907-70-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate is used as a building block for the development of new drugs and bioactive molecules, leveraging its ability to interact with biological systems for therapeutic purposes.
Used in Organic Synthesis:
Ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate is employed as a key intermediate in the synthesis of various organic compounds, contributing to the advancement of chemical research and the creation of novel chemical entities.
Used as a Reference Standard:
In the fields of analytical and forensic chemistry, Ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate is used as a reference standard to ensure the accuracy and reliability of chemical analyses and forensic investigations.
Used in Chemical and Biological Research:
Ethyl 5-amino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate's unique structure and properties make it a valuable tool for studying the reactivity and behavior of pyrazole derivatives, furthering our understanding of these chemical entities and their potential applications in various scientific disciplines.

Upstream product

• 144918-37-6 (E)-ethyl 2-cyano-3-ethoxyacrylate 
• 2924-16-5 3-fluorophenylhydrazine hydrochloride 
• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 658-27-5 m-fluorophenylhydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 

Downstream Products

• 1148051-67-5 ethyl 5-diacetylamino-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate 
• 1613395-06-4 3-[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[1-(3-fluorophenyl)-5-(furan-3-yl)-1H-pyrazol-4-yl]pyrrolidin-2-one 
• 1613395-67-7 ethyl 5-iodo-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylate 
• 1567126-75-3 5-iodo-1-(3-fluorophenyl)-1H-pyrazole-4-carboxylic acid 
• 1613395-68-8 5-iodo-1-(3-fluorophenyl)-1H-pyrazol-4-yl-carbamic acid 1,1-dimethylethyl ester 
• 1613395-69-9 C₁₈H₂₀FN₃O₃ 
• 1613395-07-5 3-[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[5-cyclopropyl-1-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrrolidin-2-one 
• 1613395-73-5 C₁₇H₂₀FN₃O₂ 
• 1508092-83-8 5-(3-cyclopropyl)-1-(3-fluorophenyl)-4-amino-1H-pyrazole 
• 1613395-76-8 C₂₁H₂₀ClF₄N₅O₂ 
• 1613395-78-0 C₂₂H₂₂ClF₄N₅O₄S 
• 1613395-80-4 5-iodo-1-(3-fluorophenyl)-1H-pyrazol 
• 1056999-20-2 1-(3-fluorophenyl)-1H-pyrazol-5-amine 

Relevant articles and documents

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition

In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.

Targeting Pim Kinases and DAPK3 to Control Hypertension

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

DIAZOLE LACTAMS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of pro-inflammatory cytokine mediated diseases, and in particular, p38 activity mediated inflammation and related conditions. The compounds have a general Fo

Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase

A novel class of fused pyrazole-derived inhibitors of p38α mitogen-activated protein kinase (MAPK) is disclosed. These inhibitors were evaluated for their ability to inhibit the p38α enzyme, the secretion of TNFα in a LPS-challenged THP1 cell line and TNF